Tina’s Wish 2027-28 Grants
Tina’s Wish 2027-28 Grants fund translational research to advance early detection and improve outcomes for gynecologic cancers, especially ovarian cancer, through biomarker and clinical innovation.
Funder: The Honorable Tina Brozman Foundation (Tina's Wish)
Due Dates: September 9, 2026 (LOI, Acceleration to Clinic Grant) | December 15, 2026 (Full Proposal, Acceleration to Clinic Grant)
Funding Amounts: $1,000,000 over 2 years (A2C Grant); Team Science Grant: $500,000/2 years; Rising Star Grant: $200,000/2 years
Summary: Supports translational research advancing early detection and improved outcomes for gynecologic cancers, especially ovarian cancer.
Key Information: LOI required for A2C Grant; full application by invitation only.
Description
The Honorable Tina Brozman Foundation (Tina’s Wish) offers multiple grant programs to accelerate research in the early detection and improved outcomes of gynecologic cancers, with a strong emphasis on ovarian cancer. The Acceleration to Clinic (A2C) Grant is the flagship program for 2027–28, designed to support investigator teams whose biomarkers have reached a defined level of clinical readiness. The A2C Grant provides not only significant funding but also expert advisory resources to help translate laboratory discoveries into clinical applications. Additional programs, including the Team Science and Rising Star Grants, are available for collaborative teams and early-career investigators focused on prevention and detection strategies.
